← Back to Search

Monoclonal Antibodies

HPN536 for Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Harpoon Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing a new drug, HPN536, to see if it is safe and effective in treating advanced cancers associated with mesothelin expression.

Eligible Conditions

Mesothelin-Associated Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assessment of Adverse Events by CTCAE 5.0 of HPN536

Determine MTD/RP2D

Efficacy of HPN536 at the recommended Phase 2 dose: overall response rate (ORR)

Trial Design

2Treatment groups

Experimental Treatment

Group I: HPN536-2001 - Part 2 (Dose Expansion)Experimental Treatment1 Intervention

HPN536 is IV administered once weekly for about 1 hour at the recommended phase 2 dose established in Part 1

Group II: HPN536-2001 - Part 1 (Dose Escalation)Experimental Treatment1 Intervention

HPN536 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

HPN536

2019

Completed Phase 2

~100

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Harpoon TherapeuticsLead Sponsor

3 Previous Clinical Trials

363 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there multiple testing facilities in the United States for this particular experiment?

"This particular clinical trial is being conducted at 16 different hospitals, some of which include the Washington University School of Medicine in St. Louis, Sarah Cannon Research Institute in Nashville, and Memorial Sloan Kettering Cancer Center in New york City."

Answered by AI

Are new participants still being accepted for this clinical trial?

"This particular trial is no longer recruiting patients, as reflected on clinicaltrials.gov. The study was originally posted on April 16th, 2019 and was most recently updated September 9th, 20202. Although this specific trial has closed recruitment, there are 2461 other trials currently enrolling individuals."

Answered by AI

Recent research and studies

Clinical Cancer ResearchJournal

Preclinical Characterization of HPN536, a Trispecific, T-cell–activating Protein Construct for the Treatment of Mesothelin-expressing Solid Tumors

Molloy, Mary Ellen, Richard J. Austin, Bryan D. Lemon, Wade H. Aaron, Vaishnavi Ganti, Adrie Jones, Susan D. Jones, et al.. 2021. “Preclinical Characterization of HPN536, a Trispecific, T-cell–activating Protein Construct for the Treatment of Mesothelin-expressing Solid Tumors”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-20-3392.

clinicaltrials.govStudy

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

2019. "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03872206.